Analysis of effector mechanisms in cancer

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

1988 • 432 citations

Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

1988 • 302 citations

Cardiorespiratory effects of immunotherapy with interleukin-2.

1989 • 246 citations

A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

1988 • 120 citations

Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2

1988 • 72 citations

Interleukin-2 therapy of human cancer: potential benefits versus toxicity.

1989 • 59 citations

In vivo function of natural killer cells as regulators of myeloid precursor cells in the spleen

1988 • 45 citations

Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.

1988 • 32 citations

Role of natural killer cells, in comparison with T lymphocytes and monocytes, in the regulation of normal human megakaryocytopoiesis in vitro.

1987 • 32 citations

Recombinant IL‐2‐activated NK cells mediate LAK activity against ovarian cancer

1988 • 30 citations

Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis

1988 • 23 citations

The Immunologic Treatment Of Cancer

1988 • 17 citations

Similarities between LAK cells derived from human thymocytes and peripheral blood lymphocytes: Expression of the NKH-1 and CD3 antigens

1988 • 15 citations

Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.

1988 • 13 citations